PDF(Pubmed)
Abstract：
We aimed to retrospectively review outcomes in patients with high-risk prostate cancer and a Gleason score ≤ 6 following modern radiotherapy. We analyzed the outcomes of 1374 patients who had undergone modern radiotherapy, comprising a high-risk low grade [HRLG] group (Gleason score ≤ 6; n = 94) and a high-risk high grade [HRHG] group (Gleason score ≥ 7, n = 1125). We included 955 patients who received brachytherapy with or without external beam radio-therapy (EBRT) and 264 who received modern EBRT (intensity-modulated radiotherapy [IMRT] or stereotactic body radiotherapy [SBRT]). At a median follow-up of 60 (2-177) months, actuarial 5-year biochemical failure-free survival rates were 97.8 and 91.8% (p = 0.017), respectively. The frequency of clinical failure in the HRLG group was less than that in the HRHG group (0% vs 5.4%, p = 0.012). The HRLG group had a better 5-year distant metastasis-free survival than the HRHG group (100% vs 96.0%, p = 0.035). As the HRLG group exhibited no clinical failure and better outcomes than the HRHG group, the HRLG group might potentially be classified as a lower-risk group.
摘要：
我们旨在回顾性回顾现代放疗后Gleason评分≤6的高危前列腺癌患者的预后。我们分析了1374例接受现代放射治疗的患者的结果，包括高风险低等级[HRLG]组（格里森评分≤6；n=94）和高风险高等级[HRHG]组（格里森评分≥7，n=1125）。我们包括955例接受或不接受外波束放射治疗（EBRT）的近距离放射治疗患者和264例接受现代EBRT（调强放射治疗[IMRT]或立体定向放射治疗[SBRT]）的患者。在60（2-177）个月的中位随访中，精算5年无生化失败生存率分别为97.8％和91.8％（p=0.017），分别。HRLG组的临床失败频率少于HRHG组（0％vs5.4％，p=0.012)。HRLG组的5年无远处转移生存率优于HRHG组（100％vs96.0％，p=0.035)。由于HRLG组没有表现出临床失败和更好的结果比HRHG组，HRLG组可能被归类为低风险组.
